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Abstract
Background: Bitopertin, a glycine reuptake inhibitor, was investigated as a novel treatment for schizophrenia. We
report all the results of a double-blind randomized study assessing safety and efficacy following 52-week adjunctive
treatment with bitopertin in Japanese patients with schizophrenia.
Methods: This study enrolled Japanese outpatients with schizophrenia who met criteria for either “negative symptoms”,
i.e., patients with persistent, predominant negative symptoms of schizophrenia even after long-term treatment
with antipsychotics or “sub-optimally controlled symptoms”, i.e., patients with insufficiently improved symptoms of
schizophrenia even after long-term treatment with antipsychotics, respectively. One hundred sixty-one patients were
randomly assigned to receive 52-week treatments with bitopertin doses of 5, 10, or 20 mg/day at ratio of 1:5:5, where
existing antipsychotics were concomitantly administered. Efficacy endpoints included Positive and Negative Syndrome
Scale (PANSS), Clinical Global Impression (CGI), and Personal and Social Performance (PSP). The purpose of the present
study is primarily to evaluate the safety, and secondarily to investigate the clinical efficacy of bitopertin.
Results: One hundred fourteen patients (71 %) completed 52-week treatment with bitopertin. Most of the adverse
events were mild or moderate in their severity. The patients in the 20-mg group experienced more adverse events
than the patients in the other two groups. Common dose-dependent adverse events were somnolence and insomnia
associated with worsening schizophrenia. The blood hemoglobin levels gradually decreased from baseline in a
dose-dependent manner, but there were no patients with the decrease below 10 g/dL that would have led to
their discontinuation. All the efficacy endpoints gradually improved in all the treatment groups for both of the
two symptoms, while there were no clear differences among the three dose groups.
Conclusions: Altogether, bitopertin was found to be generally safe and well-tolerated for the treatment of patients
with schizophrenia. All three bitopertin treated groups showed improvements in all the efficacy endpoints for both of
the two symptoms, i.e., “negative symptoms” and “sub-optimally controlled symptoms”, throughout the duration of the
study.
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Background
The negative symptoms of schizophrenia, characterized
by the absence or loss of certain behaviors such as flat
affect, account for most of the poor functional outcomes
in patients with schizophrenia [1]. This core feature of
schizophrenia includes both primary persisting negative
symptoms and secondary negative symptoms that are
related to extrapyramidal symptoms (EPS), depressive
and/or psychotic symptoms. Therapeutic interventions
in this disease with existing antipsychotics elicit partial
beneficial effects on some of the key symptoms, however
negative symptoms still persist in most of the patients
[2]. As a consequence, many patients are left with nega-
tive symptoms even after their positive symptoms have
been mitigated.
Additionally the majority of patients with schizophrenia
do not fully respond to antipsychotics, and it has been re-
ported that approximately 70 % of patients treated with
antipsychotics do not achieve symptomatic remission after
3 years treatment [3]. The remaining positive symptoms
of schizophrenia significantly increase the risk of relapse
and re-hospitalization [3], and therefore decrease QOL
and functioning [4, 5]. This population of patients referred
to as “sub-optimally” treated patients represents a majority
of schizophrenic patients.
A strong unmet need for better treatments, including
safe adjunctive treatments that can be given in combin-
ation with currently available antipsychotics would un-
doubtedly exists to improve therapeutic efficacy against
the above-mentioned symptoms [6–8].
Bitopertin is a small molecule with a novel mode of ac-
tion that was designed on a basis of the working hypoth-
esis that the hypo-functioning of the glutamatergic
receptors within the brain, particularly the N-methyl-D-
aspartate (NMDA) receptors (NMDA-R) [9, 10], is impli-
cated in the pathophysiology of schizophrenia. This work-
ing hypothesis is repeatedly supported by the variety of
pharmacological activities elicited by phencyclidine, keta-
mine and/or other NMDA receptor antagonists, because
these compounds consistently induce clinical symptoms
that are reminiscent of schizophrenia. Either phencyclid-
ine or ketamine administrations to experimental animals
produces positive- or negative- symptom like behavioral
changes and cognitive deteriorations in these animals [11].
As glycine is reported to be an obligatory co-agonist of
glutamate at the NMDA-R complex, one possible pharma-
cological intervention is to enhance the functions of the
NMDA-R within the brain by elevating extracellular levels
of glycine in the local microenvironment adjacent to the
synaptic NMDA-R. Glycine elevations can be achieved
through the inhibition of the glycine transporter 1
(GlyT1), which is known to be responsible for glycine
removal from the synaptic cleft [9, 12]. An endogenous
glycine transporter inhibitor, sarcosine, has been shown to
be of help as short-term treatment for acutely ill schizo-
phrenia [13, 14], chronically stable schizophrenia [15], and
major depression [16], but not for treatment-resistant
schizophrenia [17]. Bitopertin, a selective novel inhibi-
tor of the GlyT1 and an orally active small molecule,
is known to dose-dependently increase the extracellu-
lar levels of glycine in the striatum of the rat brain as
well as in the cerebrospinal fluid of both the rat and
healthy volunteers [18, 19].
This randomized double-blind clinical study was under-
taken to evaluate the safety and efficacy profile of the three
doses of bitopertin (5, 10, and 20 mg/day) as administering
52-week adjunctive treatment to existing antipsychotics in
Japanese patients with “negative” symptoms or “sub-opti-
mally controlled” symptoms, respectively. No placebo arm
was established to prevent patients from dropping out
from the study and to evaluate the long-term safety profile
as the main purpose. Aside from this study, six global
phase III studies including placebo arms were completed
recently and the results are going to be published.
Methods
Study design
The present multi-center, randomized, double-blind phase
III study was conducted at 35 clinical sites in Japan
between August, 2011 and December, 2013, in compliance
with the principles of the “Declaration of Helsinki” and in
adherence with the “Good Clinical Practice” (JapicCTI-
No.: JapicCTI-111627). The study protocol received
institutional review board approvals prior to the study
initiations (Additional file 1: List of the institutional review
boards), and written, informed consent was given by all the
participants prior to the study enrollments. Within 30 days
after the informed consent was obtained, screening tests
were performed, the eligibility of patients for this study
was confirmed, and the stability of the patient’s symptoms
was evaluated. Finally, patients were randomly assigned
(1:5:5) to receive 52-week treatments with respective 5, 10,
or 20 mg of bitopertin as an adjunct therapy to existing
antipsychotics, which was followed by a 4-week follow-up
period after the last dose of bitopertin was administered.
The film-coated tablets for oral administration were
manufactured by F. Hoffmann-La Roche, Ltd. For random
allocations, a minimization method was employed to
minimize imbalance between the dose groups in each of
the two symptom groups in the factors including the type
of the primary antipsychotics (atypical or typical) and age
(under 65 or not). Glycine is essential for the heme synthe-
sis in the erythroid progenitors and reticulocytes [20] and
is taken into these cells via GlyT1 [21], and bitopertin, a
glycine reuptake inhibitor, is known to potentially reduce
the blood hemoglobin levels. Thus, the results of several
relevant laboratory tests were blinded during the study
period to prevent potential unblinding.
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Study population
The present study enrolled Japanese outpatients suffer-
ing from schizophrenia aged 18 and older. They were
assigned to either group, the “negative symptom group”
(stable patients with persistent, predominant negative
symptoms of schizophrenia despite the treatments with
antipsychotics) or the “sub-optimally controlled symp-
tom group” (stable patients with insufficiently improved
symptoms of schizophrenia despite the treatments with
antipsychotics), respectively.
To be enrolled, participants were required to be stable
on one or two antipsychotics with the exception of
clozapine, whose total combined dose levels should not
exceed 6 mg of risperidone equivalents, and to have
hemoglobin levels of 12 g/dL or above because bitoper-
tin potentially reduces hemoglobin levels.
The key inclusion criteria in the “negative symptom
group” were, (1) a total score of greater than or equal to
40 on the sum of the 14 Positive and Negative Syndrome
Scale (PANSS) [22] items constituting negative symptom
factor score (NSFS) defined by the sum of PANSS items
N1, N2, N3, N4, N6, G7, and G16, and PANSS disorga-
nized thought/cognition factor scores defined by the
sum of PANSS items P2, N5, G5, G10, G11, G13, and
G15 [23], (2) a score of less than or equal to 22 on the
sum of the 8 items of PANSS positive symptom factor
score (PSFS) defined by the sum of PANSS items P1, P3,
P5, P6, N7, G1, G9, and G12 [23], and a score of four on
two or fewer of the items P1, P3, P6, and G9, and none
with a score of five or higher. Additionally, (3) a score of
four or higher based on Clinical Global Impression
(CGI)–Severity of illness (CGI-S) negative symptoms [24]
was required. The key exclusion criteria in the “negative
symptom group” were, (1) depressive symptoms defined
by Calgary Depression Scale for Schizophrenia (CDSS)
score of nine or higher, and (2) a score of three or higher
based on Clinical Global Impression of Movement Sever-
ity (CGI-MS) in the parkinsonism of the Extrapyramidal
Symptoms Rating Scale–Abbreviated (ESRS-A).
The key inclusion criteria in the “sub-optimally con-
trolled symptom group” were, (1) a PANSS total score of
greater than or equal to 70, (2) a score of four or higher
on two or more of the items P1, P3, P6, and G9, and (3) a
score of four or higher based on CGI-S positive symptoms
[24]. The key exclusion criteria in the “sub-optimally
controlled symptom group” were patients in remission
defined per all scores of three or lower on the PANSS
items P1, P2, P3, G5, G9, N1, N4, and N6 [25].
Assessment measures
The study visits were scheduled at screening, baseline, 2,
4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks
from baseline. Medication compliance was checked by
investigators at every visit.
The primary objective of the present study was to
assess the safety. Safety evaluations, therefore, included
adverse events (AEs), Columbia Suicide Severity Rating
Scale (C-SSRS) for the assessment of suicidal tendency,
laboratory tests, vital signs, 12-lead electrocardiogram,
ESRS-A for the assessment of EPS, and ophthalmo-
logical examinations.
In this study, clinical efficacy evaluations were carried
out as a secondary purpose. Trained and certified raters
were solely instructed to assess PANSS scores. Both
PANSS NSFS and PANSS PSFS were thought to be the
most suitable endpoints for evaluating each respective
“negative” and “sub-optimally controlled” symptoms
because these were used as primary endpoints in global
bitopertin phase III studies being carried out. Efficacy
parameters included CGI-S, CGI–Improvement (CGI-I)
[24], and Personal and Social Performance (PSP) [26].
Negative symptoms assessed both in terms of severity,
CGI-S, and improvement, CGI-I, were included for the
evaluation of the “negative symptom group”. Similarly,
positive symptoms assessed both CGI-S and CGI-I were
included for the evaluation of the “sub-optimally controlled
symptom group”.
Statistical analysis
The safety population consisted of all the patients who
received at least one dose of the study medication. All
the efficacy analyses were based on the intent-to-treat
(ITT) population that comprised all the randomized
patients who received at least one dose of the study
medication and who had at least one post-baseline
efficacy assessment.
The demographic characteristics of patients enrolled
in the present study, and all the safety and efficacy mea-
surements were summarized using descriptive statistics.
The efficacy analyses were performed in each two
symptom groups. Statistical hypothesis testing was not
conducted, because the primary purpose of the present
study was to evaluate the safety profile of bitopertin.
The data were analyzed using SAS (version 9.1, Cary,
NC, USA).
A target sample size planned was 165 patients (5 mg,
15 patients; 10 mg, 75 patients; 20 mg, 75 patients). This
sample size was not determined according to the power
calculation, but was determined to meet the requirement




Out of 204 patients who gave informed consents, 161
completed a prospective run-in period and were random-
ized to the three dosing arms (Fig. 1). Fifteen patients, 73
patients, and 73 patients were assigned to the 5, 10, and
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20-mg groups, respectively. A total of 161 patients were
thus treated with bitopertin. While 114 out of 161 patients
(71 %) completed the 52-week treatment period, 47
patients (29 %) did not complete the 52-week treatment
period.
The reasons for the withdrawals were “adverse event”
in 21 patients (13 %), “refused treatment or did not
cooperate” in 14 patients (9 %), “withdrew consent” in
five patients (3 %), “insufficient therapeutic response” in
two patients (1 %), “violation of inclusion and exclusion
criteria” in two patients (1 %), and “others” in three
patients (2 %), respectively. No apparent differences were
observed among the dose groups in the proportions of
patients withdrawn and their reasons.
Patient baseline and demographic characteristics
One hundred five patients (65 %) were enrolled to the
“negative symptom group”, and 56 patients (35 %) were
to the “sub-optimally controlled symptom group”. The
majority of the patients were on one of the following
primary atypical antipsychotic drugs: risperidone, olan-
zapine, aripiprazole, or paliperidone (Table 1).
The ratios of males to females were 12/3, 51/22, and
47/26 in the 5, 10, and 20-mg groups, respectively. In
these three groups, the means of age (and ranges) were
41.8 (22–64), 39.9 (18–67), and 41.8 (18–70) years,
respectively. Thus, no apparent imbalances among the
three dose groups were observed.
Efficacy outcome
The results of the following efficacy measures that were
evaluated at the last observation (at Week 52 or at the
timing of a discontinuation of treatment) are shown in
Table 2, including the mean changes from baseline in
PANSS factor scores [23], CGI-S, PSP, proportions of
responders (a 20 % or greater improvement) in PANSS
NSFS/PANSS PSFS, and proportions of responders
(“very much improved” or “much improved”) in CGI-I.
Negative symptom group
In the “negative symptom group”, the means of PANSS
NSFS at baseline in each three dose groups were ranged
from 25.9 to 26.8, and those of PANSS PSFS were ranged
from 16.9 to 18.0, respectively. In all the three groups,
PANSS NSFS gradually decreased from the first
assessment point at Week 4 (Fig. 2). The mean changes
from baseline of PANSS NSFS (standard deviation (SD),
the numbers of patients) at the last observation were −4.8
(4.1, n = 10), −4.9 (4.7, n = 47), and −4.9 (6.0, n = 47) in the
5, 10, and 20-mg groups, respectively. In each three dose
groups, the proportions of responders in the PANSS NSFS
at the last observation were 60 %, 57 %, and 49 %, respect-
ively. The mean changes (SD) of the PANSS total score at
the last observation were −7.7 (5.7), −11.0 (12.5), and
−10.3 (15.9) in each three dose groups, respectively.
The mean changes from baseline (SD) in CGI-S of the
negative symptoms at the last observation were −0.8
(1.0), −0.8 (1.0), and −0.9 (1.2) in the 5, 10, and 20-mg
groups, respectively. In each three dose groups, the
proportions of responders in CGI-I of the negative
symptoms at the last observation were 20 %, 19 %, and
26 %, respectively.
Furthermore, the PSP total score gradually increased
from the first assessment point at Week 4 in all the
three dose groups (Fig. 3). The mean changes (SD) of
the PSP total score at the last observation were 7.2 (7.3),
7.3 (11.1), and 7.0 (13.8), in each three dose groups,
respectively.
Fig. 1 Patient flow diagram
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Sub-optimally controlled symptom group
In the “sub-optimally controlled symptom group”, the
means of PANSS PSFS at baseline in each three dose
groups were ranged from 26.2 to 26.5, and those of the
PANSS NSFS were ranged from 22.2 to 24.2, respectively.
In all the three dose groups, PANSS PSFS gradually
decreased from the first assessment point at Week 4
(Fig. 4). The mean changes from baseline of PANSS PSFS
(SD, number of patients) at the last observation were −4.2
(5.0, n = 5), −3.9 (4.5, n = 25), and −2.1 (5.9, n = 25) in the
5, 10, and 20-mg groups, respectively. In each three dose
groups, the proportions of responders in the PANSS PSFS
at the last observation were 40 %, 56 %, and 28 %, respect-
ively. The mean changes (SD) of the PANSS total score at
the last observation were −9.4 (12.7), −11.0 (14.0), and
−7.5 (14.6) in each three dose groups, respectively.
The mean changes from baseline (SD) in CGI-S of the
positive symptoms at the last observation were −0.8
(1.1), −0.9 (1.2), and −0.6 (1.2) in the 5, 10, and 20-mg
groups, respectively. In each three dose groups, the
proportions of responders in CGI-I of the positive symp-
toms at the last observation were 20 %, 24 %, and 16 %,
respectively.
Furthermore, the PSP total score gradually increased
from the first assessment point at Week 4 in all the
three dose groups (Fig. 5). The mean changes (SD) of
the PSP total score at the last observation were 10.6
(14.4), 5.0 (7.4), and 6.8 (11.6) in each three dose groups,
respectively.
Safety measures
In total, 411 AEs were reported in 142 out of 161 pa-
tients (88.2 %) (Table 3). AEs included nasopharyngitis
(39.1 %), somnolence (16.8 %), worsening of schizophre-
nia (10.6 %), headache (7.5 %), insomnia associated with
worsening schizophrenia (7.5 %), and other events (5.0 %
or less), respectively. The incidences of AEs increased
dose-dependently, and were 73.3 %, 87.7 %, 91.8 %, in
the 5, 10, and 20-mg groups, respectively. Regarding the
AEs with the incidence of ≥5.0 %, both somnolence and
insomnia associated with worsening schizophrenia took
place in a dose related manner, i.e., in the 5, 10, and 20-
mg groups, the respective incidences of somnolence
were 0 %, 12.3 %, 24.7 %, and those of insomnia were 0
%, 4.1 %, 12.3 %, respectively.
In total, 139 adverse drug reactions (ADRs) were re-
ported in 78 out of 161 patients (48.4 %) (Table 3).
ADRs included somnolence (16.1 %), worsening of
schizophrenia (7.5 %), insomnia associated with worsen-
ing schizophrenia (3.7 %), parkinsonism (3.1 %), and
other events (2.5 % or less), respectively. The incidences
of ADRs dose-dependently increased, and were 13.3 %,
47.9 %, 56.2 %, in the 5, 10, and 20-mg groups,
respectively.
No apparent differences were observed in the inci-
dences of severe AEs among the three dose groups. The
incidences of severe AEs were 6.7 % (one patient), 2.7 %
(two patients), 2.7 % (two patients), in the 5, 10, and 20-
mg groups, respectively. The severity of the most AEs
were mild or moderate.
Nine serious AEs occurred in eight out of 161 patients
(5.0 %). In the serious AEs, the causal relationships to
bitopertin were not ruled out in three cases of worsening
of schizophrenia i.e., two cases and one case in the
respective 10 and 20-mg groups, and one case of
neuroleptic malignant syndrome in the 10-mg group.
Neuroleptic malignant syndrome occurred 4 weeks later
after a 3-month treatment with bitopertin, and the
patient started to take olanzapine prior to the event
during the follow-up period.









Male, n (%) 12 (80) 51 (70) 47 (64)
Age in years, mean (SD) 41.8 (11.9) 39.9 (12.2) 41.8 (13.8)
BMI (kg/m2), mean (SD) 27.0 (4.9) 26.0 (4.2) 25.4 (4.9)
Schizophrenia type, n (%)
Paranoid 11 (73) 43 (59) 38 (52)
Disorganized 1 (7) 11 (15) 10 (14)
Catatonic - 2 (3) -
Undifferentiated - 10 (14) 7 (10)
Residual 3 (20) 7 (10) 18 (25)
Previous antipsychotics frequently
used, n (%)
Risperidone 4 (27) 8 (11) 12 (16)
Aripiprazole 2 (13) 6 (8) 13 (18)
Olanzapine 1 (7) 7 (10) 9 (12)
Primary antipsychotic treatment
Type of Antipsychotics, n (%)
Atypical 14 (93) 67 (92) 68 (93)
Typical 1 (7) 6 (8) 5 (7)
Route, n (%)
P.O. 11 (73) 69 (95) 67 (92)
Infusion 4 (27) 4 (5) 6 (8)
Primary Antipsychotics, n (%)
Risperidone 4 (27) 18 (25) 17 (23)
Olanzapine 5 (33) 19 (26) 15 (21)
Aripiprazole 2 (13) 16 (22) 20 (27)
Paliperidone 1 (7) 4 (5) 9 (12)
Others 3 (20) 16 (22) 12 (16)
Abbreviations: SD standard deviation
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The proportion of patients with AEs leading to drug
discontinuations was as low as 13.0 %, and the proportion
increased dose-dependently (6.7 %, 9.6 %, 17.8 %, in the 5,
10, and 20-mg groups, respectively). There were no AEs
indicating drug dependency or withdrawal symptoms. Fur-
thermore, the incidences of AEs were similar in both the
“negative symptom group” and “sub-optimally controlled
symptom group”, i.e., 88.6 % (93/105 patients; 249 events)
and 87.5 % (49/56 patients; 162 events), respectively.
The mean blood hemoglobin levels decreased gradually
in a dose-related manner from baseline, and the values
remained stable throughout the treatment periods exam-
ined, i.e., after Week 8 up to Week 52 in all the three dose
groups (Fig. 6). These mean changes were within the
normal range. After a 4-week follow-up period, the values
returned to baseline in both the 5 and 10-mg groups,
while the values did not return to baseline in the 20-mg
group. In two patients, however, the blood hemoglobin
Table 2 Results of efficacy measures at last observation
Negative symptom Sub-optimally controlled symptom
5 mg (n = 10) 10 mg (n = 47) 20 mg (n = 48) 5 mg (n = 5) 10 mg (n = 25) 20 mg (n = 25)
PANSS, mean (SD)
Total score
Baseline 78.8 (9.9) 79.7 (10.3) 80.5 (7.4) 87.2 (10.4) 88.4 (12.2) 91.0 (13.6)
Change −7.7 (5.7) −11.0 (12.5) −10.3 (15.9) −9.4 (12.7) −11.0 (14.0) −7.5 (14.6)
Negative symptom factor score
Baseline 25.9 (4.5) 26.7 (4.7) 26.8 (4.4) 22.2 (6.2) 22.6 (5.7) 24.2 (6.4)
Change −4.8 (4.1) −4.9 (4.7) −4.9 (6.0) −1.6 (3.7) −3.7 (4.9) −2.5 (4.8)
Positive symptom factor score
Baseline 16.9 (3.3) 17.3 (3.5) 18.0 (3.2) 26.2 (6.0) 26.4 (3.8) 26.5 (5.1)
Change −0.9 (0.9) −1.7 (2.8) −1.4 (3.8) −4.2 (5.0) −3.9 (4.5) −2.1 (5.9)
Disorganized thought/cognition factor score
Baseline 19.3 (2.5) 19.3 (4.3) 19.2 (3.0) 18.2 (2.9) 19.2 (3.7) 20.8 (4.8)
Change −1.7 (1.9) −2.5 (3.2) −2.3 (3.6) −1.8 (1.8) −1.8 (3.0) −1.4 (3.0)
Uncontrolled hostility/excitement factor score
Baseline 6.5 (2.0) 7.1 (2.4) 7.0 (2.3) 10.4 (4.4) 9.5 (3.2) 9.0 (2.5)
Change 0.5 (1.2) −0.6 (1.6) −0.5 (2.2) −1.0 (1.4) −0.9 (2.3) −0.7 (2.0)
Anxiety/depression factor score
Baseline 10.2 (2.4) 9.3 (2.6) 9.6 (2.8) 10.2 (2.5) 10.7 (2.7) 10.5 (2.8)
Change −0.8 (1.2) −1.3 (2.2) −1.3 (2.3) −0.8 (1.9) −0.8 (2.1) −0.9 (2.5)
Responder in each symptoma, n (%) 6 (60) 27 (57) 23 (49) 2 (40) 14 (56) 7 (28)
CGI, mean (SD)
CGI-S of overall symptom
Baseline 3.6 (0.5) 4.1 (0.6) 4.2 (0.6) 4.2 (0.4) 4.2 (0.5) 4.4 (0.6)
Change −0.1 (0.3) −0.6 (0.9) −0.6 (1.2) −1.0 (1.0) −0.8 (1.0) −0.6 (1.0)
CGI-S in each symptom
Baseline 4.4 (0.7) 4.4 (0.6) 4.5 (0.7) 4.2 (0.4) 4.3 (0.6) 4.3 (0.6)
Change −0.8 (1.0) −0.8 (1.0) −0.9 (1.2) −0.8 (1.1) −0.9 (1.2) −0.6 (1.2)
CGI-I of overall symptomb, n (%) 0 (0) 8 (17) 12 (26) 1 (20) 7 (28) 3 (12)
CGI-I in each symptomb, n (%) 2 (20) 9 (19) 12 (26) 1 (20) 6 (24) 4 (16)
PSP total score, mean (SD)
Baseline 54.0 (16.2) 50.0 (14.2) 46.5 (16.0) 45.4 (18.8) 48.8 (15.6) 46.1 (12.5)
Change 7.2 (7.3) 7.3 (11.1) 7.0 (13.8) 10.6 (14.4) 5.0 (7.4) 6.8 (11.6)
Abbreviations: CGI clinical global impression, CGI-I CGI-improvement, CGI-S CGI-severity of illness, PANSS positive and negative syndrome scale, PSP personal and
social performance, SD standard deviation
a20 % or greater improvement of PANSS negative symptom factor score in the negative symptom group or of PANSS positive symptom factor score in the
sub-optimally controlled symptom group. The scores in each item were transformed from 1–7 to 0–6
bResponder of CGI-I is defined as a patient has a response of “very much improved” or “much improved”
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levels met the withdrawal criteria during the study (de-
creases of 25 % and more from baseline), while the levels
increased after drug withdrawals. The levels in one patient
were 17.2, 12.7, and 14.5 g/dL at baseline and Week 32
(drug withdrawal), and after a 4-week follow-up period,
respectively, and those in the other patient were 16.3,
11.8, and 14.4 g/dL at baseline and Week 16 (drug with-
drawal), and after a 4-week follow-up period, respectively.
In the two patients, bleeding was not reported. No other
patients met the other withdrawal criteria related to the
blood hemoglobin levels of under 10 g/dL.
Finally, no clinically relevant changes in vital signs,
laboratory tests, 12-lead electrocardiogram, and ESRS-A
were observed.
Discussion
The hypo-functioning of NMDA-R within the brain has
attracted great attention from neuroscientists as well as
psychiatrists as one of the possible pathogenetic mecha-
nisms underlying schizophrenia [9, 10]. Bitopertin is a
glycine reuptake inhibitor that is expected to eventually
activate neuronal NMDA-R by increasing the concentra-
tions of glycine in the synaptic cleft, since glycine is an
obligatory co-agonist of glutamate at the site of NMDA-R
complex within the brain. The present phase III, multi-
center, randomized, double-blind study was undertaken
primarily to investigate the safety profile of bitopertin, and
secondarily to examine whether or not bitopertin allevi-
ates symptoms in patients who exhibit two distinct clinical
symptoms of schizophrenia; the “negative symptom” and
the “sub-optimally controlled symptom”. Bitopertin was
administered at doses of 5, 10, and 20 mg/day as an ad-
junctive treatment to existing antipsychotics for 52 weeks.
The present study demonstrated that long-term treat-
ment with bitopertin for successive 52 weeks was safe and
well tolerated as far as the three dose levels of 5, 10, and
Fig. 2 Mean changes in the PANSS negative symptom factor score in the negative symptom group. Abbreviations: LO last observation, W52
Week 52
Fig. 3 Mean changes in the personal and social performance total score in the negative symptom group. Abbreviations: LO last observation, PSP
personal and social performance, W52 Week 52
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20 mg/day of bitopertin were concerned. The overall
safety profile of bitopertin was similar to those reported in
the two global phase II studies previously conducted; one
was performed as an 8-week adjunctive therapy in patients
with negative symptoms [27], and the other was per-
formed as a 4-week monotherapy in patients with acute
exacerbation of schizophrenia [28]. In the present study,
neither dose-dependent increases in the incidences nor
those in the severity of the AEs viewed as clinically
relevant, e.g., EPS, were observed even in the presence of
existing antipsychotics. In other words, the concomi-
tant administrations of bitopertin with existing antipsy-
chotics did not aggravate the safety profiles of the
antipsychotic drugs.
Regarding the clinical efficacy outcomes, in both of
the two respective patient population with “negative
symptoms” and “sub-optimally controlled symptoms”, all
the endpoints improved throughout the treatment
period, compared with the baseline. No clear-cut dose-
related responses among the three dose groups, however,
were observed.
As one of the features in the present study, most of
the patients enrolled completed 52-week treatment
with bitopertin (71 %). In a meta-analysis of mainten-
ance treatment with antipsychotics, the proportions of
patients completed study periods were 70 % in the anti-
psychotics group, and the mean study duration weighted
by sample sizes of individual trials was 9 months [29].
Hence, the proportion of patients completed in the
present study is comparable to those of previous trials.
This finding indicates that the safety profile following
long-term treatment with bitopertin is favorable where
Fig. 4 Mean changes in the PANSS positive symptom factor score in the sub-optimally controlled symptom group. Abbreviations: LO last observation,
W52 Week 52
Fig. 5 Mean changes in the personal and social performance scale score in the sub-optimally controlled symptom group. Abbreviations: LO last
observation, PSP personal and social performance, W52 Week 52
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existing antipsychotics were concomitantly administered.
The high proportion together with no apparent imbalance
of the proportion among the three dose groups enabled
evaluation of the safety profile following long-term treat-
ment with bitopertin. In this regard, of particular interest
was to test whether or not any detrimental influences of
bitopertin on the hemoglobin levels would be seen after
long-term treatment, because schizophrenia requires life-
long treatment. Glycine is essential for the heme synthesis
in the erythroid progenitors and reticulocytes [20] and is
taken into these cells via GlyT1 [21]. Thus, it seems
plausible that chronic treatments with bitopertin, a glycine
reuptake inhibitor, may cause decreases in hemoglobin
levels. In the previous global phase II study with 8-week
bitopertin treatment at doses ranging between 10 and
60 mg/day, dose-dependent decreases in the hemoglobin
levels were also observed [27]. The present study revealed
that the decreased levels of hemoglobin following long-
term treatment with bitopertin remained within the
normal range, and increased towards baseline after drug
withdrawals, suggesting that bitopertin is a reversible
glycine reuptake inhibitor whose hemoglobin decreasing
Table 3 Common AEs and ADRs
5 mg (n = 15) 10 mg (n = 73) 20 mg (n = 73) Total (n = 161)
Patients with at least 1 AE, n (%) 11 (73.3) 64 (87.7) 67 (91.8) 142 (88.2)
Total number of AEs, n 23 165 223 411
AEs with an incidence of more than 5 %
Nasopharyngitis 3 (20.0) 31 (42.5) 29 (39.7) 63 (39.1)
Somnolence - 9 (12.3) 18 (24.7) 27 (16.8)
Worsening of schizophreniaa 2 (13.3) 4 (5.5) 11 (15.1) 17 (10.6)
Headache - 5 (6.8) 7 (9.6) 12 (7.5)
Insomnia associated with worsening schizophreniab - 3 (4.1) 9 (12.3) 12 (7.5)
Patients with at least 1 ADR, n (%) 2 (13.3) 35 (47.9) 41 (56.2) 78 (48.4)
Total number of ADRs, n 2 56 81 139
ADRs with an incidence of more than 2 %
Somnolence - 8 (11.0) 18 (24.7) 26 (16.1)
Worsening of schizophreniaa 1 (6.7) 4 (5.5) 7 (9.6) 12 (7.5)
Insomnia associated with worsening schizophreniab 2 (2.7) 4 (5.5) 6 (3.7)
Parkinsonism 1 (6.7) 4 (5.5) - 5 (3.1)
Headache - 1 (1.4) 3 (4.1) 4 (2.5)
Akathisia - 1 (1.4) 3 (4.1) 4 (2.5)
Abbreviations: ADR adverse drug reaction, AE adverse event
a“Worsening of schizophrenia” was coded to “schizophrenia” by Medical Dictionary for Regulatory Activities (MedDRA) version 14.1 preferred term
b“Insomnia associated with worsening schizophrenia” was coded to “insomnia related to another mental condition” by MedDRA version 14.1 preferred term
Fig. 6 Mean hemoglobin levels. Abbreviations: FU after a 4-week follow up period, LO last observation, W52 Week 52
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effects may be clinically tolerable even at the highest daily
dose level of 20 mg investigated. Nonetheless, it is im-
portant to note that, since the exclusion criterion of
hemoglobin levels was established less than 12 g/dL,
drawing conclusions about any long-term effects of
bitopertin in patients whose hemoglobin levels are
below this level may be difficult. Thus, further clinical
studies undoubtedly need to be performed to clarify
this issue.
As shown in the present study, most of the AEs observed
were mild or moderate in their severity, and few were eval-
uated as serious or severe AEs. Among the three different
doses of bitopertin examined, the patients in the 20-mg
group experienced more AEs than the patients in the other
two dose groups, i.e., 5-mg and 10-mg groups. The most
commonly observed AEs with a dose-dependency were
somnolence and insomnia associated with worsening
schizophrenia. A proportion of the patients with AEs
leading to drug discontinuations was as low as 13.0 %; in
two patients of the 20-mg group, the hemoglobin levels
decreased and met the withdrawal criteria, decreases of
25 % and more from baseline. Altogether, it can be
concluded that bitopertin is tolerable even after the long-
term administration period of 52-week.
Regarding the clinical efficacy of bitopertin, since no
placebo group was established in the present study, it
seems hard to evaluate it. This is partly because definite
placebo effects were repeatedly reported in the variety of
clinical studies where compounds for the treatments of
various types of psychiatric disorders were included [30].
In any event, the efficacy of bitopertin will have to be
considered based on the outcomes of the present study
in conjunction with those of six other global phase III
studies being conducted in which placebo arms were
included.
All the efficacy endpoints in the present study, i.e.,
PANSS, PSP, CGI-S, CGI-I scores at the last observation,
apparently improved in all the three treatment groups for
both two respective patient population with “negative
symptoms” and “sub-optimally controlled symptoms”.
While no clear-cut dose-responses were manifested among
the three dose groups, the improvements became clear
from the first assessment made at Week 4 following
administrations of bitopertin. Among others, noteworthy
is a finding that clinically meaningful improvements of the
PSP scores over seven points, a clinically relevant effect in
stable patients [31], were observed at the last observation
for both of the two symptoms.
Conclusions
Bitopertin was administered at doses of 5, 10, and
20 mg as an adjunctive treatment to existing antipsy-
chotics for 52 weeks in respective two patient popula-
tion of stable “negative symptoms” or “sub-optimally
controlled symptoms”. No clinically relevant AEs, labora-
tory test abnormalities, 12-lead electrocardiogram abnor-
malities, and others were observed. It can be envisaged
that bitopertin was generally safe and well-tolerated for
the treatment of schizophrenia. All the efficacy endpoints,
i.e., PANSS, PSP, CGI-S, and CGI-I scores, gradually
improved in all the treatment groups for both of the two
symptoms throughout the treatment period.
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